UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

Fierce Biotech·Mar 2

This story is reported by Fierce Biotech. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Pressure builds as back-and-forth between uniQure and FDA intensifies

Fierce Biotech·Mar 5

2

FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’

BioSpace·Nov 24

3

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy

Stocktwits·Feb 26

4

UniQure stock plunges after FDA rejects gene therapy data, Sell-side Comments

Investing.com Canada·Mar 2

5

StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data

Genetic Engineering and Biotechnology News·Dec 7

6

UPDATED: Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy

Fierce Biotech·Mar 5

7

Oryon shines out of stealth with $21M to fight Parkinson's disease

Fierce Biotech·Mar 23